CD200 Checkpoint Reversal:A Novel Approach to Immunotherapy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-2234
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Local Angiotensin II Contributes to Tumor Resistance to Checkpoint Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

A Joint Approach to Immunotherapy Biomarkers

Cancer Discovery
Oncology
2018English

Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma

Cell
BiochemistryGeneticsMolecular Biology
2019English

Prediction of Clinical Response to Checkpoint Blockade Immunotherapy Is Improved With Ensembling

2019English

Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2020English

CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy Following Haploidentical Transplantation for Advanced Leukemia

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

WEE1 Kinase Inhibition Reverses G2/M Cell Cycle Checkpoint Activation to Sensitize Cancer Cells to Immunotherapy

OncoImmunology
OncologyAllergyImmunology
2018English

Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy

Mayo Clinic Proceedings
Medicine
2019English

Novel Approaches of Immunotherapy

Current Treatment Options in Allergy
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy